Short Interest in DiaMedica Therapeutics Inc. (NASDAQ:DMAC) Sees Significant Increase

DiaMedica Therapeutics Inc. (NASDAQ:DMAC - Get Free Report) experienced a notable rise in short interest in February. According to the latest data as of February 15th, short interest amounted to 232,300 shares. This reflects a 21.1% increase from the January 31st figure of 191,900 shares. With an average daily trading volume of 113,800 shares, the current short-interest ratio stands at 2.0 days.

Recent Stock Performance of DiaMedica Therapeutics

On Thursday, DiaMedica's stock fell by $0.13, bringing its price to $5.95. The trading volume reached 39,720 shares, which is below the average of 68,370 shares. The company's 50-day moving average price is $5.91, while its 200-day moving average sits at $4.98. Currently, DiaMedica Therapeutics has a market capitalization of $254.43 million, a negative price-to-earnings ratio of -10.62, and a beta of 1.52. The stock has experienced a 52-week low of $2.14 and a high of $6.82.

Institutional Investment Movements

Recent activity among institutional investors and hedge funds reveals various adjustments to their positions in DiaMedica Therapeutics. Dimensional Fund Advisors LP increased its holdings by 14.0% in the 4th quarter, owning now 19,339 shares valued at approximately $105,000 after acquiring an additional 2,380 shares. In the previous quarter, Point72 Asia Singapore Pte. Ltd. established a new stake in DiaMedica valued at around $40,000. Furthermore, LPL Financial LLC expanded its position by 8.2%, totaling 152,000 shares valued at $825,000 after purchasing 11,500 additional shares. Balyasny Asset Management L.P. and Y Intercept Hong Kong Ltd. also initiated new positions in the 4th quarter, valued at approximately $79,000 and $81,000 respectively. Altogether, institutional investors and hedge funds own 10.12% of DiaMedica's stock.

Analyst Ratings on DiaMedica Therapeutics

In a recent report, HC Wainwright reiterated a "buy" rating for DiaMedica Therapeutics and set a target price of $7.00 for the stock.

Overview of DiaMedica Therapeutics

DiaMedica Therapeutics Inc. is a clinical-stage biopharmaceutical company that aims to enhance the lives of individuals dealing with serious health conditions, particularly focusing on acute ischemic stroke. Its primary candidate, DM199, is a recombinant version of the human tissue kallikrein-1 protein and is currently undergoing Phase II/III trials for treating acute ischemic stroke, as well as in Phase 2 trials for managing cardio-renal diseases.

stocks, DMAC, shortinterest